Recurrent Cutaneous T-cell lymphoma

Also known as: Recurrent T-Cell Lymphoma / Relapsed T-Cell Lymphoma / T-Cell Lymphoma Relapsed / T-cell lymphoma recurrent / T-cell lymphoma NOS recurrent

DrugDrug NameDrug Description
DB02546VorinostatVorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs. [Wikipedia]
DrugDrug NamePhaseStatusCount
DB01234Dexamethasone0Terminated1
DB00059Pegaspargase0Terminated1
DB11945Avelumab2Recruiting1
DB01008Busulfan2Not Yet Recruiting1
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB01073Fludarabine2Not Yet Recruiting1
DB01073Fludarabine2Recruiting1
DB01042Melphalan2Not Yet Recruiting1
DB14219Monomethyl fumarate2Not Yet Recruiting1
DB00688Mycophenolate mofetil2Not Yet Recruiting1
DB00688Mycophenolate mofetil2Recruiting1
DB00877Sirolimus2Recruiting1
DB00864Tacrolimus2Not Yet Recruiting1
DB11581Venetoclax2Not Yet Recruiting1
DB06813Pralatrexate3Active Not Recruiting1